Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net income	$ 54.5	$ 62.7	$ 82.6
Adjustments to reconcile to net cash provided by operating activities:
Share-based compensation	26.7	23.2	15.2
Depreciation and amortization	110.7	62.2	42.6
Deferred income taxes	(1.1)	8.6	3.3
Change in fair value of contingent consideration, net	24.8	3.1	7.8
Impairment of IPR&D intangible asset	12.0	0.0	0.0
Amortization of deferred financing costs	3.0	0.9	1.7
Other	(0.2)	0.2	1.2
Changes in operating assets and liabilities:
Accounts receivable	(8.2)	(94.2)	(4.8)
Inventories	(16.7)	(1.9)	6.1
Income taxes	(11.7)	(5.1)	20.1
Prepaid expenses and other assets	(27.4)	(7.9)	(3.7)
Accounts payable	16.5	(7.0)	16.1
Accrued expenses and other liabilities	(15.1)	(11.6)	1.6
Accrued compensation	4.2	8.4	3.3
Deferred revenue	16.0	0.2	15.0
Net cash provided by operating activities:	188.0	41.8	208.1
Cash flows from investing activities:
Purchases of property, plant and equipment and other	(86.9)	(72.1)	(54.8)
Milestone payment from asset acquisition	(10.0)	0.0	0.0
Asset acquisitions	0.0	0.0	(77.6)
Business acquisitions, net of cash acquired	0.0	(827.7)	(117.5)
Proceeds from sale of assets	0.0	2.6	0.0
Net cash used in investing activities:	(96.9)	(897.2)	(249.9)
Cash flows from financing activities:
Proceeds from revolving credit facility	130.0	348.0	0.0
Proceeds from term loan facility	0.0	450.0	0.0
Principal payments on revolving credit facility	(105.0)	0.0	0.0
Principal payments on term loan facility	(11.3)	(2.8)	0.0
Proceeds from issuance of common stock upon exercise of stock options	8.2	15.9	19.3
Debt issuance costs	0.0	(13.4)	(1.4)
Taxes paid on behalf of employees for equity activity	(7.4)	(6.6)	(4.3)
Payment of notes payable to Aptevo	0.0	0.0	(20.0)
Contingent consideration payments	(50.4)	(3.4)	(10.9)
Receipts and payments of restricted cash	0.0	1.1	(1.0)
Purchase of treasury stock	0.0	(0.1)	(33.1)
Net cash (used in) provided by financing activities	(35.9)	788.7	(51.4)
Effect of exchange rate changes on cash and cash equivalents	0.4	(0.2)	0.0
Net increase (decrease) in cash and cash equivalents and restricted cash	55.6	(66.9)	(93.2)
Cash and cash equivalents and restricted cash at beginning of year	112.4	179.3	272.5
Cash and cash equivalents and restricted cash at end of year	168.0	112.4	179.3
Supplemental disclosure of cash flow information:
Cash paid during the year for interest	34.5	10.2	8.4
Cash paid during the year for income taxes	30.8	14.0	12.0
Supplemental information on non-cash investing and financing activities:
Issuance of common stock to acquire Adapt Pharma	0.0	37.7	0.0
Purchases of property, plant and equipment unpaid at year end	12.3	14.7	4.6
Reconciliation of cash and cash equivalents and restricted cash:
Total	$ 168.0	$ 179.3	$ 179.3